FAQContact usTerms of servicePrivacy Policy

Discontinuing statin use might raise risk of Parkinsonís

Thursday July 25, 2013
Printer Icon
Select Text Size: Zoom In Zoom Out
Share this Nurse.com Article
rss feed
People who stop taking statins may be at an increased risk for developing Parkinsonís disease, according to a Taiwanese study.

Previous studies on the relationship between statins and the risk of Parkinsonís disease have had inconsistent results, researchers noted in background information for the study, which was published July 24 on the website of the journal Neurology.

The new study involved 43,810 people in Taiwan who were taking statins and did not have Parkinsonís disease. Taiwanís compulsory national health insurance program reimbursement policy requests that physicians stop prescribing statins once the patientís cholesterol reaches the treatment goal, which is contrary to standard treatment in the United States.

"This policy allowed us to see whether there was any difference in the risk of Parkinsonís in people who stopped taking statins compared to the ones who kept taking them," the studyís author, Jou-Wei Lin, MD, PhD, of National Taiwan University in Taipei, said in a news release.

The study found a difference between two types of statins. The use of lipophilic statins such as simvastatin and atorvastatin was associated with a reduced risk of Parkinsonís, while no such association was found for hydrophilic statins such as pravastatin and rosuvastatin.

Those who stopped taking the fat-soluble statins were 58% more likely to develop Parkinsonís disease than those who kept taking the drugs, an absolute risk of 2.65 cases per 1 million person-days. This result was consistent even after adjusting for other conditions such as diabetes and hypertension. The association was strongest among female users for simvastatin and among the elderly for atorvastatin.

The researchers also looked at how many people taking the two types of statins developed Parkinsonís disease, compared with the number of person-days spent on the medication, to come up with an incidence rate.

A total of 25 people taking fat-soluble statins developed Parkinsonís from a total of nearly 15 million person-days on the drugs, for a rate of 1.68 cases per 1 million person-days on the drugs. For the water-soluble statins, 14 people developed Parkinsonís from nearly 4 million person-days on the drugs, for a rate of 3.52 cases per 1million person-days on the drugs.

"The fat-soluble statins are better able to cross the blood-brain barrier than the water-soluble statins," Lin said.

Study abstract: www.neurology.org/content/early/2013/07/24/WNL.0b013e31829d873c.short

Send comments to editor@nurse.com or post comments below.